Bank of New York Mellon Corp Sells 39,372 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Bank of New York Mellon Corp lessened its holdings in OPKO Health, Inc. (NASDAQ:OPK) by 3.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,024,907 shares of the biotechnology company’s stock after selling 39,372 shares during the quarter. Bank of New York Mellon Corp owned 0.15% of OPKO Health worth $1,507,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Rubric Capital Management LP lifted its position in OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after purchasing an additional 4,284,336 shares during the period. Barclays PLC lifted its position in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 329,870 shares during the period. BNP Paribas Financial Markets lifted its position in OPKO Health by 736.7% during the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 217,450 shares during the period. Intech Investment Management LLC bought a new stake in OPKO Health during the third quarter worth about $190,000. Finally, FMR LLC lifted its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on OPK. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Wednesday, March 12th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Wednesday.

OPKO Health Stock Down 1.1 %

OPK stock opened at $1.80 on Friday. The stock has a market capitalization of $1.21 billion, a P/E ratio of -9.47 and a beta of 1.70. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 12 month low of $0.92 and a 12 month high of $2.04. The firm has a 50-day moving average price of $1.65 and a 200-day moving average price of $1.57.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. As a group, equities research analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the stock in a transaction dated Friday, January 17th. The stock was bought at an average price of $1.47 per share, with a total value of $220,500.00. Following the completion of the purchase, the chief executive officer now directly owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. This represents a 0.07 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 964,971 shares of company stock valued at $1,493,692 over the last quarter. 47.26% of the stock is owned by company insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.